It could. I think the important thing to understand about data protection is that it typically operates in parallel to patent protection and runs now for 10 years. It did run for eight, and patent protection is 20 years from filing, so typically data protection is almost redundant in a way. It's subsumed within the patent term, so it will really depend on how many drugs are coming onto the market in the future, biologics, for which there is less exclusive time left under patent than there is under data protection. That's a very difficult thing to forecast. I think a bigger picture of what that supports in terms of a policy adjustment is a more robust PMPRB to equip us with the tools that we need to more closely scrutinize these types of drugs.
On November 6th, 2018. See this statement in context.